Profile data is unavailable for this security.
About the company
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
- Revenue in USD (TTM)1.00m
- Net income in USD-8.57m
- Incorporated2000
- Employees13.00
- LocationMediciNova IncSUITE 650, 4275 EXECUTIVE SQUARELA JOLLA 92037United StatesUSA
- Phone+1 (858) 373-1500
- Fax+1 (858) 404-0048
- Websitehttps://medicinova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | 6.29m | -112.67m | 61.90m | 62.00 | -- | 0.3817 | -- | 9.84 | -1.95 | -1.95 | 0.1089 | 2.70 | 0.0248 | -- | -- | 101,419.40 | -44.34 | -35.47 | -48.77 | -37.14 | -- | -- | -1,791.87 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Cidara Therapeutics Inc | 63.91m | -22.93m | 62.09m | 69.00 | -- | -- | -- | 0.9715 | -0.2528 | -0.2528 | 0.7136 | -0.0906 | 1.12 | -- | 5.79 | 926,159.40 | -40.05 | -65.23 | -804.74 | -154.37 | 45.03 | -- | -35.88 | -100.61 | 0.8122 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 63.22m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| Aligos Therapeutics Inc | 15.53m | -87.68m | 63.27m | 66.00 | -- | 0.6656 | -- | 4.07 | -1.82 | -1.82 | 0.3204 | 1.22 | 0.1041 | -- | -- | 235,287.90 | -58.80 | -51.20 | -72.71 | -59.73 | -- | -- | -564.61 | -1,399.21 | -- | -- | 0.0026 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| VolitionRX Ltd | 775.30k | -35.32m | 63.96m | 110.00 | -- | -- | -- | 82.49 | -0.504 | -0.504 | 0.0109 | -0.0953 | 0.0335 | -- | 4.92 | 7,048.18 | -154.29 | -111.92 | -- | -196.20 | -- | -- | -4,601.71 | -10,793.31 | -- | -280.52 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Mural Oncology PLC | 0.00 | -207.45m | 63.97m | 117.00 | -- | 0.2391 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.57m | 64.74m | 13.00 | -- | 1.04 | -- | 64.74 | -0.1748 | -0.1748 | 0.0204 | 1.27 | 0.0142 | -- | -- | 76,923.08 | -12.21 | -15.36 | -12.80 | -15.90 | -- | -- | -857.15 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| SCYNEXIS Inc | 140.14m | 67.04m | 65.36m | 29.00 | 1.34 | 0.8822 | -- | 0.4664 | 1.29 | 1.29 | 2.90 | 1.96 | 1.30 | 34.76 | 133.41 | 4,832,483.00 | 62.01 | -30.02 | 73.55 | -36.35 | 88.85 | -- | 47.84 | -86.76 | 6.26 | 33.49 | 0.1428 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Carisma Therapeutics Inc | 14.92m | -86.88m | 66.26m | 107.00 | -- | 2.44 | -- | 4.44 | -3.47 | -3.47 | 0.446 | 0.6533 | 0.107 | -- | -- | 139,429.90 | -62.34 | -30.87 | -74.95 | -34.47 | -- | -- | -582.34 | -255.66 | -- | -- | 0.0318 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 66.61m | 230.00 | -- | -- | -- | 1.35 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Celularity Inc | 14.79m | -181.41m | 67.09m | 225.00 | -- | 1.97 | -- | 4.54 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to MediciNova Inc's reporting currency: US Dollar USD
17.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 3D Investment Partners Pte Ltd.as of 19 Apr 2023 | 5.50m | 11.22% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 690.77k | 1.41% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 607.73k | 1.24% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2023 | 447.96k | 0.91% |
| Geode Capital Management LLCas of 31 Dec 2023 | 435.73k | 0.89% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 174.10k | 0.36% |
| Merrill Lynch International (Investment Management)as of 31 Dec 2023 | 167.96k | 0.34% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 157.20k | 0.32% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 153.56k | 0.31% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 152.53k | 0.31% |
More ▼
Data from 31 Dec 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
